EGFR-IN-204 (Example 1) is a HER2 exon 20 mutation inhibitor with selectivity for wild-type EGFR. EGFR-IN-204 exerts antiproliferative effects on cells dependent on HER2 exon 20 YVMA insertion mutation and wild-type HER2, and shows strong selectivity over cells dependent on wild-type EGFR. EGFR-IN-204 is applicable to non-small cell lung cancer research.

EGFR-IN-203 is a EGFR kinase domain inhibitor targeting EGFRT790M/C797S/V948R. EGFR-IN-203 stably binds to the allosteric pocket of EGFR in an inactive conformation. EGFR-IN-203 can be used in research related to cancers such as non-small cell lung cancer.

EGFR-IN-202 is an epidermal growth factor receptor (EGFR) inhibitor that selectively targets EGFR exon 20 insertion mutations. EGFR-IN-202 can be used in research related to non-small cell lung cancer.

EGFR-IN-200 is an inhibitor targeting EGFR, TNF-α, and the IL-6/GP130 complex, which potently targets human EGFR (IC50=0.03 μM), TNF-α (IC50=3.1 μM), and the IL-6/GP130 complex (IC50=1.6 μM). EGFR-IN-200 binds to the ATP pocket of EGFR, the trimer interface of TNF-α, and the cytokine-receptor interface of IL-6/GP130, induces G2/M cell cycle arrest, apoptosis, and antiproliferative activity. EGFR-IN-200 exhibits high gastrointestinal absorbability, low BBB permeability, and complies with the Lipinski's rule. EGFR-IN-200 can be used for the research of lung cancer and breast adenocarcinoma.

EGFR-IN-199 is a selective and potent EGFR inhibitor with IC50 values of 1.1 nM and 1.4 nM for purified EGFR WT and EGFRT790M/L858R kinases. EGFR-IN-199 can be used for the research of cancer.

EGFR-IN-197 is an EGFR inhibitor with IC50 values of 19.5 nM and 12.0 nM against EGFRL858R/T790M and EGFRL858R/T790M/C797S, respectively. EGFR-IN-197 arrests the cell cycle of NCI-H1975 cells at the G2/M phase, while inhibiting their proliferation, colony formation and migration; it also inhibits mitochondrial translocation and upregulates mitochondrial H2S levels. EGFR-IN-197 disrupts anti-apoptotic signaling pathways by regulating apoptosis-related proteins; it induces DNA damage and activates pro-apoptotic pathways to trigger apoptosis. EGFR-IN-197 can be used in studies related to non-small cell lung cancer (NSCLC).

EGFR-IN-193 is an EGFR inhibitor, which can be used to synthesize PROTACs as target protein ligands, such as PROTAC EGFR degrader 17.

EGFR-IN-189 (Compound 7) is a selective covalent epidermal growth factor receptor (EGFR) inhibitor with an IC50 of 200 nM. EGFR-IN-189 can effectively inhibit the C797S mutant type of EGFR. EGFR-IN-189 can inhibit cancer cells proliferation and inhibit EGFR phosphorylation and downstream ERK1/2 phosphorylation. EGFR-IN-189 can be used for research of nonsmall cell lung cancer.

EGFR-IN-179 (Compound 8d) is an EGFR inhibitor (IC50: 0.068 μM for EGFR L858R/T790M/C797S; 2.56 μM for EGFR-WT-TK). EGFR-IN-179 has anticancer activity against non-small cell lung cancer.

EGFR-IN-177 is a potent EGFR inhibitor with IC50s of 0.32, 1.04, 0.65, 0.67, 0.48, 0.55 and 0.38 nM against EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S, EGFR D746-750, EGFR D746-750/C797S, EGFR D770_N77linsNPG, and EGFR WT. EGFR-IN-177 inhibits lung cancer proliferation and EGFR phosphorylation. EGFR-IN-177 can be used for the study of cancers such as non-small cell lung cancer.

EGFR/VEGFR2-IN-11 is an EGFR/VEGFR2 inhibitor with IC50 values of 0.62 μM (human EGFR), 2.26 μM (human VEGFR-2), 17.38 μM (human COX-2), and 19.31 μM (human tubulin). EGFR/VEGFR2-IN-11 inhibits COX-2 activity and tubulin polymerization. EGFR/VEGFR2-IN-11 induces cell cycle arrest and apoptosis. EGFR/VEGFR2-IN-11 exerts selective and antiproliferative activity against human cancer cells. EGFR/VEGFR2-IN-11 can be used for the research of colon carcinoma, breast carcinoma, leukemia, lymphoma, glioblastoma.

EGFR/BRAFV600E-IN-7 is a dual EGFR and BRAFV600E kinase inhibitor with human IC50 values of 0.12 μM, 0.80 μM, 1.20 μM for EGFR and 0.05 μM, 0.22 μM, 0.78 μM for BRAFV600E.EGFR/BRAFV600E-IN-7 interacts with key ATP-binding site residues of EGFR and BRAFV600E, including hydrogen bonding with EGFR Met769 and BRAFV600E Cys532.EGFR/BRAFV600E-IN-7 induces apoptosis via caspase-3/8/9 activation, modulates Bax and Bcl-2 expression, scavenges free radicals, and exhibits antiproliferative activity against human cancer cell lines.EGFR/BRAFV600E-IN-7 displays drug-likeness with no PAINS/Brenk structural alerts per in silico predictions.EGFR/BRAFV600E-IN-7 can be used for the research of colon cancer, pancreatic cancer, lung cancer, breast cancer.

EGFR kinase-IN-8 (Compound H8b) is an EGFR inhibitor. EGFR kinase-IN-8 potently inhibits both triple-mutated EGFRL858R/T790M/C797S (IC50 = 3.86 nM) and double-mutated EGFRL858R/T790M (IC50 = 1.23 nM). EGFR kinase-IN-8 suppresses EGFR phosphorylation and downstream AKT, STAT3, and MAPK signaling. EGFR kinase-IN-8 exhibits anticancer activity against non-small cell lung cancer.

EG36 is a selective E. coli DnaK inhibitor that inhibits DnaK ATPase activity at a concentration of 100 μM. EG36 directly binds to the nucleotide-binding domain (NBD) of E. coli DnaK by disrupting the DnaK-DnaJ interaction. EG36 can be used for research on bacterial infectious diseases.

EDP-420 (EP-013420; S-013420) is an orally active antibacterial agent. EDP-420 inhibits the Mycobacterium avium complex (MAC) in macrophages. EDP-420 reduces bacterial counts in a mouse model of macrolide infection. EDP-420 inhibits pneumococcal activity in a rabbit model of meningitis. EDP-420 can be used in research on inflammatory infectious diseases such as meningitis.

Echinocandin B (purity>65%) (SL 7810 (purity>65%)) is a lipopeptide antifungal antibiotic. Echinocandin B (purity>65%) is produced by Aspergillus nidulans. Echinocandin B (purity>65%) inhibits β-1,3-glucan activity, thereby blocking the biosynthesis of fungal cell walls. Echinocandin B (purity>65%) exhibits activity against a variety of Aspergillus species.

EC0652 is a PSMA imaging agent with SPECT imaging capability. EC0652 can be used for the research of metastatic castration-resistant prostate cancer.

E-6837 is a selective and orally active 5-HT6 receptor ligand. E-6837 demonstrates partial agonism at a presumably silent rat 5-HT6 receptor and full agonism at a constitutively active human 5-HT6 receptor by monitoring the cAMP signaling pathway. E-6837 induces hypophagia, reduces fat mass and body weight, and improves glycemic control. E-6837 can be used for the research of obesity.

E5700 is an orally active squalene synthase inhibitor, antimalarial agent and antifungal agent with an IC50 of 0.49 nM (without PPi) against squalene synthase from T. cruzi epimastigotes. E5700 shows antiparasitic activities against Trypanosoma cruzi. E5700 inhibits the growth and alters the lipid prolife and the ultrastructure of a multiple agent-resistant C. tropicalis strain. E5700 is a potent and selective inhibitor of the growth of Leishmania amazonensis.

E3 Ligase Ligand-linker Conjugate 226 is a synthetic E3 ligase ligand-linker conjugate that can be used to synthesize PROTACs, such as PROTAC IRAK3 degrader-2. GXF-111 is a IRAK PROTAC degrader with anti-tumor activity.

E3 Ligase Ligand-linker Conjugate 225 is an E3 ligase ligand-linker conjugate used for the synthesis of PROTACs; it consists of the PEG-based linker Bis-Tos-PEG3 and the VHL-type E3 ubiquitin ligase ligand VH 101 thiol. E3 Ligase Ligand-linker Conjugate 225 can be further coupled with a target protein ligand—such as MT-4—to synthesize the PROTAC TG2 Degrader-3.

E3 Ligase Ligand-linker Conjugate 224 is an E3 Ligase Ligand-Linker Conjugate that incorporates a ligand for VHL and a PROTAC linker. E3 Ligase Ligand-linker Conjugate 224 can be used for synthesis of KRAS G12D PROTAC degrader MS243.

E3 Ligase Ligand-linker Conjugate 215 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 215 can be used to synthesize STAT3 PROTAC Degrader S3D5.

E3 Ligase Ligand-linker Conjugate 214 is an E3 ligase ligand-linker conjugate containing a Von Hippel-Lindau (VHL) ligand and a linker. E3 Ligase Ligand-linker Conjugate 214 can bind to a target protein ligand to form a PROTAC molecule, PROTAC LSD1 Degrader 1.

E2072 is a selective, orally active competitive inhibitor of glutamate carboxypeptidase II (GCPII) with a Ki of 10 nM. E2072 alleviates established thermal hyperalgesia in a rat model of chronic constriction injury. E2072 prevents oxaliplatin-induced reductions in nerve conduction velocity and amplitude in mice. E2072 is applicable to research related to neuropathic pain and neuropathy.

E12LA6B6O3 is an amino lipid that can be used to prepare nanoparticles for drug delivery, such as mRNA.

MW-436 (E 0471) hydrochloride is a benzofuran compound with antiarrhythmic effects. MW-436 hydrochloride can be used for the research of cardiovascular disease.

DZX19 (Compound C02) is an orally active, selective TRK inhibitor with a TRKA IC50 value of 1.32 nM, a TRKB IC50 of 2.28 nM, and a TRKC IC50 of 4.05 nM. DZX19 inhibits the kinase activities of wild-type TRKA, TRKA mutants (G595R, F589L, G667C), wild-type TRKB, and wild-type TRKC, and suppresses the phosphorylation of TRKA as well as its downstream AKT and ERK signaling pathways. DZX19 induces apoptosis. DZX19 inhibits tumor growth in a colorectal cancer xenograft mouse model. DZX19 is applicable for the research of colorectal cancer.

Dyrk1A-IN-17 is an orally active and blood-brain barrier-permeable multi-kinase inhibitor. Dyrk1A-IN-17 reduces the excessive phosphorylation of α-synuclein by inhibiting four kinases (ABL1, DYRK1A, GSK3β, and LRRK2) and stabilizing microtubules. Dyrk1A-IN-17 is applicable for research on neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease.

Dyrk1A-IN-16 is a selective, brain-penetrant and ATP-competitive Dyrk1A inhibitor with a IC50 of 53 nM. Dyrk1A-IN-16 displays high selectivity across a broad kinase panel (specific for DYRK kinases) with nanomolar potency. Dyrk1A-IN-16 impairs neurosphere self-renewal, cell invasion, and EGFR stability in vitro. Dyrk1A-IN-16 inhibits tumor growth and prolongs survival in vivo. Dyrk1A-IN-16 has potential for glioblastoma (GBM) research.